2024 Partners
If you'd like to become a partner for the 3rd annual Liquid Biopsy Surveillance Summit. Get in touch here to partner and learn more about our bespoke sponsorship opportunities.
Program Partner
Burning Rock Dx specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology. With the unique capability and experience in global trials, we are looking for partnerships to advance the field of companion diagnostics in order to achieve better patient outcomes.
Program Partner
Personalis, Inc. is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. Our patented ACE (Accuracy and Content Enhanced) Technology forms the foundation of all Personalis products. ACE Technology improves every individual step in the next-generation sequencing (NGS) process, from nucleic acid extraction to sequencing assays, to data analytics. This makes it possible for us to achieve augmented coverage of difficult-to-sequence genomic regions that are missed with the use of conventional sequencing techniques. Using this comprehensive approach, we provide genomic data of the highest quality and accuracy to help biopharma drive their immuno-oncology clinical and biomarker discovery programs, thus enabling the rational design and development of effective cancer immunotherapies.
Program Partner
Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care.
Program Partner
Natera has developed Signatera™, a tumor-informed circulating tumor DNA (ctDNA) assay for molecular residual disease (MRD) detection, recurrence monitoring, and treatment response monitoring in patients previously diagnosed with cancer. With >60 peer-reviewed publications and >260 congress presentations, Signatera™ is clinically validated across multiple cancer types and reimbursed by Medicare for colorectal cancer, muscle-invasive bladder cancer, and immunotherapy monitoring. Signatera™ is used in multiple on-going prospective studies led by drug developers and researchers, has FDA Breakthrough Device Designation and CE mark, and is available globally. Learn more at https://www.natera.com/clinical-trials
Meeting Partner
BioIVT enables smarter science and accelerates medical breakthroughs by delivering high-quality personalized biospecimen solutions and research services to life science and diagnostic industries. Recognized as an industry leader, BioIVT specializes in control and disease state samples including human and animal tissues or preparations, ADME-Tox products and research services, cell and gene therapy products, blood, and other biofluids.